Staidson and Pivotal Collaborate in Trial of Progressive Severe COVID-19 Patients
Staidson and Pivotal have announced a new strategic collaboration to assess Staidson´s investigational product BDB-001 in a Europe-based clinical trial in progressive severe COVID-19 patients caused by SARS-CoV-2. This clinical trial is a multicenter, open-label, randomized and controlled study. Sixty patients will be enrolled in the trial, half of them will be administered the drug and the other half will follow the standard of care used at the corresponding center.
For more information, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
